3-[2-(3-Chloro-4-propan-2-yloxyphenyl)-[1,3]oxazolo[5,4-b]pyridin-6-yl]propanoic acid | 1382936-44-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-[2-(3-Chloro-4-propan-2-yloxyphenyl)-[1,3]oxazolo[5,4-b]pyridin-6-yl]propanoic acid
• CAS: 1382936-44-8
• 化学式: C₁₈H₁₇ClN₂O₄
• 分子量: 360.797
• InChiKey: VPQCOTNQPANAJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  85.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-氯-4-异丙氧基苯甲酸 在 tris-(dibenzylideneacetone)dipalladium(0) 、 草酰氯 、 六氯乙烷 、 水 、 caesium carbonate 、 三乙胺 、 三苯基膦 、 sodium hydroxide 、 tri tert-butylphosphoniumtetrafluoroborate 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 2.0h， 生成 3-[2-(3-Chloro-4-propan-2-yloxyphenyl)-[1,3]oxazolo[5,4-b]pyridin-6-yl]propanoic acid
  参考文献：
  名称：

  Identification of benzoxazole analogs as novel, S1P3 sparing S1P1 agonists

  摘要：

  A novel series of benzoxazole-derived S1P(1) agonists were designed based on scaffold hopping molecular design strategy combined with computational approaches. Extensive SAR studies led to the discovery of compound 17d as a selective S1P(1) agonist (over S1P(3)) with high CNS penetration and favorable DMPK properties. 17d also demonstrated in vivo pharmacological efficacy to reduce blood lymphocyte in mice after oral administration. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.095

文献信息

• Identification of benzoxazole analogs as novel, S1P3 sparing S1P1 agonists
  作者：Guanghui Deng、Qinghua Meng、Qian Liu、Xuesong Xu、Qiongfeng Xu、Feng Ren、Taylor B. Guo、Hongtao Lu、Jia-Ning Xiang、John D. Elliott、Xichen Lin

  DOI：10.1016/j.bmcl.2012.04.095

  日期：2012.6

  A novel series of benzoxazole-derived S1P(1) agonists were designed based on scaffold hopping molecular design strategy combined with computational approaches. Extensive SAR studies led to the discovery of compound 17d as a selective S1P(1) agonist (over S1P(3)) with high CNS penetration and favorable DMPK properties. 17d also demonstrated in vivo pharmacological efficacy to reduce blood lymphocyte in mice after oral administration. (C) 2012 Elsevier Ltd. All rights reserved.